Sign in →

Test Code KINM Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Manual


Necessary Information


Pathologist's name, address, and phone number are required.



Specimen Required


This is not an orderable test. Order PATHC / Pathology Consultation. The consultant will determine the need for special stains.

 

Specimen Type:

Preferred: Formalin-fixed, paraffin-embedded tissue block containing neuroendocrine tumor of the pancreas or gastrointestinal (GI) tract including metastases.

Acceptable: 2 Unstained sections, containing neuroendocrine tumor of the pancreas or GI tract including metastases, on charged slides cut at 4 microns <1 month ago. Tissue on the slides should have been fixed in 10% neutral buffered formalin.

Supplies: Pathology Packaging Kit (T554)

Collection Instructions:           

1. Submit formalin-fixed, paraffin-embedded tissue block.

2. Include accompanying pathology report stating the final diagnosis. If not available, a preliminary diagnosis is acceptable.

3. Attach the green pathology address label included in the kit to the outside of the transport container.

Additional Information: Paraffin block will be returned with the final report.


Forms

If not ordering electronically, complete, print, and send a Pathology Test Request Form (T246) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/pathology-request-form.pdf).

Secondary ID

71667

Useful For

Determining proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with neuroendocrine tumors of the pancreas or gastrointestinal tract including metastases

Testing Algorithm

Includes pathology consultation charged separately.

Method Name

This is not an orderable test. Order PATHC / Pathology Consultation. The consultant will determine the need for special stains.

 

Immunohistochemistry, Semi- Quantitation, Hot-Spot Technique

Reporting Name

Ki67 GI/Pancreas NET IHC Manual

Specimen Type

Special

Specimen Stability Information

Specimen Type Temperature Time
Special Ambient (preferred)
  Refrigerated 

Reject Due To

Hemolysis

NA

Lipemia

NA

Icterus

NA

Other

NA

Clinical Information

Ki-67(MIB-1 clone) is a monoclonal antibody that reacts with cells undergoing DNA synthesis by binding to the Ki-67 antigen, a marker known to be expressed only in proliferating cells. By measuring the amount of tumor cells expressing Ki-67, an estimate of DNA synthesis can be determined. Studies suggest that Ki-67(MIB-1) analysis of paraffin-embedded tissue specimens may provide useful prognostic information in various tumor types.

Reference Values

This is not an orderable test. Order PATHC / Pathology Consultation. The consultant will determine the need for special stains.

 

Varies by tumor type; values reported from 0% to 100%

Interpretation

Results will be reported as a percentage of tumor cells staining positive for Ki-67(MIB-1). Semi-quantitative Ki-67(MIB-1) results should be interpreted within the clinical context for which the test was ordered.

Clinical Reference

1. Bosman F, Carneiro F, Hruban R, et al: WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer, 2010

2. Hochwald SN, Zee S, Conlon KC, et al: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633-2642

3. Klimstra DS, Modlin IR, Coppola D, et al: The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2009;39:707-712

4. Klimstra DS, Modlin IR, Adsay NV, et al: Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010;34:300-313

5. Pathology and Genetics Tumours of Endocrine Organs. Edited by RA DeLellis, RV Lloyd, PU Heitz, C Eng. IARC Press, 2004

Day(s) and Time(s) Performed

Monday through Friday; 8 a.m.-5 p.m.

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

88360

LOINC Code Information

Test ID Test Order Name Order LOINC Value
KINM Ki67 GI/Pancreas NET IHC Manual In Process

 

Result ID Test Result Name Result LOINC Value
71674 Interpretation In Process
71675 Participated in the Interpretation In Process
71676 Report electronically signed by In Process
71677 Material Received 81178-6
71678 Disclaimer 62364-5
71845 Case Number In Process